Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Nucleus RadioPharma secured a Series A extension funding with AstraZeneca investment.

PRIVATEJun 05, 2024about 2 years ago

Round Type

Series A

DavidsonManufacturingBiotechnologyHealth Carepharmaceuticals

Investors

University Of MissouriEcho Global Granger Management Mercy HealthFox Chase Cancer CenterEclipse VenturesMayo ClinicGe HealthcareAstra Zeneca

Description

Nucleus RadioPharma announced the closing of a Series A extension round with new investor AstraZeneca, joining existing investors GE Healthcare, Mayo Clinic, and others. The funding will be used to expand development, supply, and commercial manufacturing capabilities to make targeted radiotherapies and theranostics more accessible to patients globally.

Company Information

Company

Nucleus RadioPharma

Location

Davidson, North Carolina, United States

About

Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization.

Related People

Suggested for you
1 contact
Verified contactsNo contacts on file at Nucleus RadioPharma yet.
Predictive Intelligence
Strategic

ML-powered predictions for Nucleus RadioPharma's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.